This site is intended for healthcare professionals only
Share this article

Pioglitazone treatment may be effective in NASH

In a recent controlled trial, researchers assessed the efficacy and safety of long-term pioglitazone therapy in improving outcomes in people with biopsy-proven non-alcoholic steatohepatitis (NASH) and either prediabetes or type 2 diabetes. Participants were randomised to receive daily pioglitazone or placebo for 18 months, along with dietary counselling. A significantly higher percentage of individuals receiving pioglitazone achieved the primary endpoint and had resolution of NASH, while a similar percentage had improvement in their fibrosis.

By Colin Kenny, GP, Dromore

In this study, 101 people with biopsy-proven NASH and prediabetes or type 2 diabetes were recruited. Participants underwent a low-calorie diet and were then randomly assigned to pioglitazone 45 mg/day or placebo for 18 months; this was followed by an 18-month open-label phase with pioglitazone treatment. The primary outcome was a reduction of at least 2 points in the non-alcoholic fatty liver disease activity score, without worsening of fibrosis.

At 18 months, compared with participants receiving placebo, a significantly higher percentage of individuals receiving pioglitazone achieved the primary endpoint (58% versus 17%) and had resolution of NASH (51% versus 19%). Similar findings were noted for improvement in fibrosis. Weight gain was significantly greater in the pioglitazone group (mean, 2.5 kg) compared with the placebo group. The investigators concluded that clinicians should consider pioglitazone for NASH in both people with and without diabetes, especially those with fibrosis. However, its use needs to be balanced with the risks for weight gain, heart failure and bone fractures.

To access the full publication, click here (log-in or purchase required)

Related content
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.